Identifying the target of CD44 monoclonal antibodies in the amelioration of murine immune thrombocytopenia using human-CD44 and Cre recombinase mouse models

使用人 CD44 和 Cre 重组酶小鼠模型确定 CD44 单克隆抗体改善小鼠免疫性血小板减少症的靶标

• 批准号: 386479
• 负责人: Kaur Gurleen
• 金额: $ 1.27万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-12-01 至 2018-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=386479&lang=en
• 关键词: Autoimmune Diseases; Cd44 Monoclonal Antibodies; Cre Recombinase Mice; Immune Thrombocytopenia; Immunotherapies; Innate Immune Cells; Intravenous Immunoglobulin; Platelets; Transgenic Mice

Intravenous immunoglobulin (IVIg) is the current treatment for a whole host of autoimmune and inflammatory disorders, including immune thrombocytopenia (ITP) which is a disorder characterized by low platelets. However, replacements for IVIg are necessary

静脉注射免疫球蛋白（IVIg）是目前治疗一系列自身免疫性和炎症性疾病的方法，包括免疫性血小板减少症（ITP），这是一种以低血小板为特征的疾病。然而，IVIg的替代品是必要的